300482 Guangzhou Wondfo Biotech
- 28.90
- +0.03+0.10%
Guangzhou Wondfo Biotech News
Foreign investors look at Chinese assets! A number of institutions have increased their stock positions
Currently, foreign investors are actively allocating RMB assets. According to the latest data from the State Administration of Foreign Exchange, in April, overseas investors made net purchases of 124.7 billion yuan of domestic bonds and 45.1 billion yuan of domestic stocks.
Wanfu Biotech (300482): Restorative growth in conventional domestic business and continued breakthroughs in overseas layout
Incident: The company released its 2023 annual report, achieving operating income of 2,765 million yuan (-51.33%), net profit of 488 million yuan (-59.26%), and net profit of non-return to mother of 415 million yuan (-62)
Wanfu Biotech (300482.SZ): As of March 31, 2024, the number of shareholders of the company was 41,501
Gelonghui, May 8 | Wanfu Biotech (300482.SZ) said on the investor interactive platform that as of March 31, 2024, the number of shareholders of the company was 41,501.
Express News | Wanfu Biotech: Respiratory triple household self-test OTC products were approved by the US FDA EUA
Wanfu Biotech (300482): New product registration and further expansion of application scenarios in the next city
The company's respiratory trifecta household self-test OTC product was authorized by the US FDA EUA and issued an announcement on May 5. Its US subsidiary's triple home test kit for the novel coronavirus, influenza A virus, and influenza B virus
Express News | Wanfu Biotech Jointly Undertakes National Key R&D Program Projects
Express News | Wang Jihua, Chairman of Wanfu Biotech: The company has moved to “qualitative growth”
Wanfu Biotech (300482) Commentary on important matters: Respiratory Trilateral Testing FDA certification is expected to increase performance
Matters: Company announcement, US subsidiary “WONDFO USA CO. , LTD” Novel Coronavirus, Influenza A Virus and Influenza B Triple Test Kit WellLife COVID-19/I
Wanfu Biotech (300482): Continued increase in profitability, diversified layout helps high-quality growth
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 2,765 million yuan (yoy -51%), realized net profit of 488 million yuan (yoy -59%), deducted from the mother
Cinda Securities released a research report on April 24 stating that it gave Wanfu Biotech (300482.SZ) a purchase rating. The main reasons for the rating include: 1) regular business continues to grow, and profitability continues to increase; 2) strengthe
Cinda Securities released a research report on April 24 stating that it gave Wanfu Biotech (300482.SZ) a purchase rating. The main reasons for the rating include: 1) regular business continues to grow, and profitability continues to increase; 2) strengthening the R&D network and diversifying product layout to help the company achieve “gradual, high-quality” growth. (Mainichi Keizai Shimbun)
Wanfu Biotech (300482): Strong growth in conventional business, the approval of the Joint Inspection Service in the US has exceeded expectations
Event: The company released its 2023 annual report and 2024 quarterly report. Achieved operating income of 2,765 billion yuan (-51.33%) and net profit to mother of 488 million yuan (-59.26%) in 2023
Wanfu Biotech (300482): Regular business continued to resume for 23 years, concurrent regular/special projects
Core idea: Regular business continues to resume. According to the company's 23 annual report, the company achieved revenue of 2,765 billion yuan (YOY -51.33%); gross profit margin 62.61% (YOY+10.79pp); net profit to mother
Express News | Wanfu Biotech: US subsidiary respiratory triple test products obtained US FDA EUA authorization
A-share pharmaceutical and medical stocks fluctuated and rebounded
Gelonghui, April 22 | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceuticals rose more than 5%.
The medical device sector rebounded underwater. Wanfu Biotech rose more than 11%, Yahuilong rose more than 6%, and many stocks such as Chunli Healthcare and Jet Biotech followed suit.
The medical device sector rebounded underwater. Wanfu Biotech rose more than 11%, Yahuilong rose more than 6%, and many stocks such as Chunli Healthcare and Jet Biotech followed suit.
Wanfu Biotech (300482): Major new product approved, optimistic about subsequent performance
The company's COVID-19 influenza A and B triple test professional product was authorized by the US FDA EUA. The company issued an announcement on April 22. Its US subsidiary obtained triple test kits for the novel coronavirus, influenza A virus, and influenza B virus from the US subsidiary
Wanfu Biotech (300482.SZ)'s revenue and net profit for the first quarter of 2024 both increased year-on-year
In the first quarter of 2024, the company achieved total revenue of 861 million yuan, an increase of 3.54% over the same period of the previous year; net profit attributable to shareholders of listed companies was 218 million yuan, an increase of 7.20% over the same period last year.
Wanfu Biotech (300482.SZ) reported 2023 annual results, net profit of 488 million yuan, a year-on-year decrease of 59.26%
According to the Zhitong Finance App, Wanfu Biotech (300482.SZ) released its 2023 annual report, with revenue of 2,765 billion yuan, a year-on-year decrease of 51.33%. Net profit attributable to shareholders of listed companies was 488 million yuan, a year-on-year decrease of 59.26%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $415 million, a year-on-year decrease of 62.46%. The basic income per share is 1.10 yuan. A cash dividend of 4 yuan (tax included) is distributed to all shareholders for every 10 shares, 0 bonus shares (tax included), and 0 shares are transferred to all shareholders for every 10 shares using the capital reserve fund. The company focuses on the body
Express News | Strategic cooperation between Wanfu Biotech and Maijie Medicine promotes the development of precision oncology
Express News | Guangzhou Intelligent Computing Consortium was formally established, and Wanfu Biotech participated in the initiative
Analysis
Price Target
No Data
